Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

10.2

Margin Of Safety %

43

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.27

EPS Last/This Y

1.5

EPS This/Next Y

1.41

Price

34.4

Target Price

50.27

Analyst Recom

1.45

Performance Q

15.2

Relative Volume

1.1

Beta

0.84

Ticker: HRMY




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04HRMY32.160.170.214168
2025-07-07HRMY32.260.170.004166
2025-07-08HRMY32.750.173.204161
2025-07-09HRMY34.310.170.704167
2025-07-10HRMY34.320.250.074469
2025-07-11HRMY34.010.250.204480
2025-07-14HRMY34.720.280.274584
2025-07-15HRMY34.790.280.834595
2025-07-16HRMY35.210.280.044603
2025-07-17HRMY36.410.282.904674
2025-07-18HRMY35.190.290.744736
2025-07-21HRMY35.130.690.051963
2025-07-22HRMY36.710.330.043525
2025-07-23HRMY37.220.270.524290
2025-07-24HRMY36.730.260.764436
2025-07-25HRMY37.550.260.014487
2025-07-28HRMY35.770.140.228051
2025-07-29HRMY35.450.140.928227
2025-07-30HRMY35.50.140.258265
2025-07-31HRMY35.060.140.918308
2025-08-01HRMY34.380.140.038318
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04HRMY32.160.390.94.18
2025-07-07HRMY32.260.391.54.18
2025-07-08HRMY32.750.396.34.18
2025-07-09HRMY34.290.3107.74.18
2025-07-10HRMY34.330.390.94.18
2025-07-11HRMY34.000.387.34.18
2025-07-14HRMY34.710.398.04.18
2025-07-15HRMY34.840.391.84.18
2025-07-16HRMY35.200.394.14.18
2025-07-17HRMY36.430.3102.94.18
2025-07-18HRMY35.200.378.14.18
2025-07-21HRMY35.230.390.74.18
2025-07-22HRMY36.670.3105.14.18
2025-07-23HRMY37.220.395.54.18
2025-07-24HRMY36.71-0.785.54.15
2025-07-25HRMY37.52-0.798.44.15
2025-07-28HRMY35.87-0.774.64.15
2025-07-29HRMY35.45-0.787.24.15
2025-07-30HRMY35.48-0.790.64.15
2025-07-31HRMY35.18-0.787.34.15
2025-08-01HRMY34.40-9.082.24.06
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04HRMY-0.87-5.308.50
2025-07-07HRMY-0.87-5.248.50
2025-07-08HRMY-0.87-5.248.50
2025-07-09HRMY-0.87-5.248.50
2025-07-10HRMY-0.87-5.248.50
2025-07-11HRMY-0.87-5.2410.12
2025-07-14HRMY-0.87-5.0910.12
2025-07-15HRMY-0.87-5.0910.12
2025-07-16HRMY-0.82-5.0910.12
2025-07-17HRMY-0.74-5.0910.12
2025-07-18HRMY-0.74-5.0910.12
2025-07-21HRMY-0.74-4.9210.12
2025-07-22HRMY-0.52-4.9210.12
2025-07-23HRMY-0.52-4.9210.12
2025-07-24HRMY-0.21-4.9210.12
2025-07-25HRMY-0.21-4.9210.20
2025-07-28HRMY-0.21-4.7610.20
2025-07-29HRMY-0.09-4.7610.20
2025-07-30HRMY-0.09-4.7610.20
2025-07-31HRMY-0.09-4.7610.20
2025-08-01HRMY-0.09-4.7610.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.78

Avg. EPS Est. Current Quarter

1.05

Avg. EPS Est. Next Quarter

1.05

Insider Transactions

-0.09

Institutional Transactions

-4.76

Beta

0.84

Average Sales Estimate Current Quarter

204

Average Sales Estimate Next Quarter

218

Fair Value

49.11

Quality Score

98

Growth Score

71

Sentiment Score

15

Actual DrawDown %

44.6

Max Drawdown 5-Year %

Target Price

50.27

P/E

13.11

Forward P/E

8.63

PEG

0.53

P/S

2.65

P/B

2.74

P/Free Cash Flow

8.92

EPS

2.62

Average EPS Est. Cur. Y​

4.06

EPS Next Y. (Est.)

5.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

20.5

Relative Volume

1.1

Return on Equity vs Sector %

-2.5

Return on Equity vs Industry %

16.1

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.12

EBIT Estimation

82.2
Harmony Biosciences Holdings, I
Sector: Healthcare
Industry: Biotechnology
Employees: 268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
stock quote shares HRMY – Harmony Biosciences Holdings, Inc. Stock Price stock today
news today HRMY – Harmony Biosciences Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HRMY – Harmony Biosciences Holdings, Inc. yahoo finance google finance
stock history HRMY – Harmony Biosciences Holdings, Inc. invest stock market
stock prices HRMY premarket after hours
ticker HRMY fair value insiders trading